ICY Overzicht aandelen Incyte Corporation, een biofarmaceutisch bedrijf, houdt zich bezig met het ontdekken, ontwikkelen en op de markt brengen van therapeutica voor hematologie/oncologie en ontstekingen en auto-immuniteit in de Verenigde Staten en internationaal. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Incyte Corporation Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Incyte Historische aandelenkoersen Huidige aandelenkoers US$64.00 52 Week Hoogtepunt US$78.52 52 Week Laag US$47.11 Bèta 0.70 1 maand verandering -3.88% 3 maanden verandering 7.45% 1 Jaar Verandering 14.65% 3 jaar verandering -0.71% 5 jaar verandering -19.41% Verandering sinds IPO 303.07%
Recent nieuws en updates
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023) Oct 29
Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024 Oct 08
Insufficient new directors Oct 01 Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer Meer updates bekijken
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023) Oct 29
Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024 Oct 08
Insufficient new directors Oct 01 Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma Aug 16
Executive VP & Chief Medical Officer recently sold €644k worth of stock Aug 15
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023) Jul 31
Executive VP of Global Medical Affairs recently sold €1.0m worth of stock Jul 30
Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024 Jul 10
Executive VP & GM of North America recently sold €1.1m worth of stock Jun 16
Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders. Jun 01 Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 16
Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 14
First quarter 2024 earnings released: EPS: US$0.76 (vs US$0.097 in 1Q 2023) May 01
Incyte Corporation, Annual General Meeting, Jun 12, 2024 May 01
Incyte Corporation Maintains Earnings Guidance for 2024 Apr 30
Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million. Apr 23
Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024 Apr 12
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS) Mar 11
Incyte Corporation Provides Earnings Guidance for 2024 Feb 14
Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022) Feb 13
Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024 Jan 24
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Incyte Corporation Provides Earning Guidance for the Full Year 2023 Nov 01
Third quarter 2023 earnings released: EPS: US$0.76 (vs US$0.51 in 3Q 2022) Oct 31 Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo Oct 12
Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023 Oct 11
Incyte Corporation Announces Executive Changes, Effective November 1, 2023 Sep 14
Executive VP & Chief Medical Officer recently sold €1.2m worth of stock Aug 06
Incyte Corporation Revises Earnings Guidance for the Year 2023 Aug 02
Second quarter 2023 earnings released: EPS: US$0.91 (vs US$0.73 in 2Q 2022) Aug 02
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25 Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023
Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023 May 09
First quarter 2023 earnings released: EPS: US$0.097 (vs US$0.17 in 1Q 2022) May 03
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa Feb 11 Incyte Corporation Provides Earnings Guidance for the Year 2023
Full year 2022 earnings released: EPS: US$1.53 (vs US$4.30 in FY 2021) Feb 08
Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis Dec 13
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology Dec 06
Third quarter 2022 earnings released: EPS: US$0.51 (vs US$0.82 in 3Q 2021) Nov 02
Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine Oct 20
Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022 Oct 12
Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors Oct 05
Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion. Oct 04
Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement Aug 27
Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021) Aug 03
Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022 Aug 03
Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo Jul 19
Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022 Jul 13
FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata Jun 14
Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa) May 21
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 May 12
Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease May 05
First quarter 2022 earnings released: EPS: US$0.17 (vs US$0.24 in 1Q 2021) May 04
Incyte Corporation, Annual General Meeting, Jun 15, 2022 May 02
Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer Apr 23
Incyte Corporation to Report Q1, 2022 Results on May 03, 2022 Apr 13
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 09
Incyte Corporation Provides Revenue Guidance for the Full Year 2022 Feb 09
Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo Dec 15 MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020) Nov 03
Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million. Sep 29 Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD) Sep 23
Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults Sep 20
Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation Sep 19
Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Aug 25
Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial Aug 05
Second quarter 2021 earnings released: EPS US$0.68 (vs US$1.33 in 2Q 2020) Aug 04
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease Jul 15
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jun 26
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis Jun 12
Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease Jun 09
Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL Jun 05
Independent Director Paul Friedman has left the company Jun 05
Incyte Corporation Announces Positive Primary Analysis from the Phase 2 Optic Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (Cp-Cml) to Be Presented At the 2021 Asco Annual Meeting May 21
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo May 18
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma May 12
First quarter 2021 earnings released: EPS US$0.24 (vs US$3.33 loss in 1Q 2020) May 05
Incyte Corporation Provides Revenue Guidance for the Full Year 2021 May 05
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation Mar 19
Eli Lilly and Company and Incyte Announce Top-Line Results from BRAVE-AA2 Mar 04 Rendement voor aandeelhouders ICY DE Biotechs DE Markt 7D -5.4% -2.9% -2.6% 1Y 14.7% -14.7% 6.9%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: ICY overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -14.7 % opleverde.
Rendement versus markt: ICY overtrof de German markt, die het afgelopen jaar een rendement opleverde van 6.9 %.
Prijsvolatiliteit Is ICY's price volatile compared to industry and market? ICY volatility ICY Average Weekly Movement 5.8% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stabiele aandelenkoers: ICY heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van ICY is het afgelopen jaar stabiel geweest.
Over het bedrijf Incyte Corporation, een biofarmaceutisch bedrijf, houdt zich bezig met het ontdekken, ontwikkelen en op de markt brengen van therapeutica voor hematologie/oncologie en ontstekingen en auto-immuniteit in de Verenigde Staten en internationaal. Het bedrijf biedt JAKAFI (ruxolitinib) aan voor de behandeling van myelofibrose met intermediair of hoog risico, polycythemia vera en steroïd-refractaire acute graft-versus-hostziekte; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) voor recidief of refractair diffuus groot B-cellymfoom; PEMAZYRE (pemigatinib), een fibroblastgroeifactorreceptorkinaseremmer die fungeert als oncogene drivers in vloeibare en vaste tumortypes; ICLUSIG (ponatinib) voor de behandeling van chronische myeloïde leukemie en Philadelphia-chromosoom positieve acute lymfoblastische leukemie; en ZYNYZ (retifanlimab-dlwr) voor de behandeling van volwassenen met metastatisch of terugkerend lokaal gevorderd Merkelcelcarcinoom, evenals OPZELURA crème voor de behandeling van atopische dermatitis. Haar producten in klinische fase omvatten retifanlimab in Fase 3 klinische studies voor plaveiselcelcarcinoom van het anale kanaal en niet-kleincellige longkanker; axatilimab, een anti-CSF-1R monoklonaal antilichaam in Fase 2 dat wordt ontwikkeld als therapie voor patiënten met chronische GVHD; INCA033989 om oncogenese af te remmen; INCB160058, dat wordt ontwikkeld als een ziekte-modificerende therapie; en INCB99280 en INCB99318 voor de behandeling van solide tumoren.
Meer tonen Incyte Corporation Samenvatting Hoe verhouden de winst en inkomsten van Incyte zich tot de beurswaarde? ICY fundamentele statistieken Marktkapitalisatie €12.38b Inkomsten(TTM ) €31.13m Inkomsten(TTM ) €3.91b
408.3x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) ICY resultatenrekening (TTM ) Inkomsten US$4.08b Kosten van inkomsten US$2.88b Brutowinst US$1.20b Overige uitgaven US$1.16b Inkomsten US$32.48m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) 0.17 Brutomarge 29.33% Nettowinstmarge 0.80% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde ICY op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/20 07:54 Aandelenkoers aan het einde van de dag 2024/12/20 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Incyte Corporation wordt gevolgd door 55 analisten. 23 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Jasper Hellweg Argus Research Company Thomas Russo Baird Ishan Majumdar Baptista Research
Toon 52 meer analisten 
